Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter

Abstract

The sponges were collected from a variety of locations in the Florida Keys and separated based on morphology and color. The samples were identified as three species, two of which are well known: V. rigida (Esper, 1794) (order Verongida, family Aplysinidae) and S. aurea (Hyatt, 1875) (order Dictyoceratida, family Thorectidae), and a third S. cerebriformis (Duchassaing & Michelotti, 1864), is less common and separated based on subtle differences of morphology and coloration, from the other two species. Several compounds were isolated and were evaluated in established animal models predictive of neurological related drug function, namely, the rodent FST and the chick anxiety-depression model.

1 . A method of treating a neurological condition in an animal host in need thereof comprising: administering to said host an effective amount of an isolated and purified marine natural product, wherein said isolated and purified marine natural product is a haloindole alkaloid, wherein said neurological condition is selected from the group consisting of depression and anxiety. 
   
   
       2 . A method of treating a neurological condition in an animal host in need thereof comprising: administering to said animal host an effective amount of a compound as depicted in formula (I), wherein formula (I) is as follows: 
     
       
         
         
             
             
         
       
     
     wherein R 5  and R 6  are the same or different halogen and the remaining R groups are hydroxy, oxy, halo, C 1 -C 12 -alkoxy, C 1 -C 12 -acyloxy, amide, lower mono or dialkyl amino, aminal, thiol, C 1 -C 12 -alkylthiol, nitro, C 1 -C 12 -alkysulfonyl, aminosulfonyl, hydroxyl sulfonyl, C 1 -C 12 -acylamino, sulphate, C 1 -C 12 -alkyl, C 1 -C 12 -acyl or aryl groups. 
   
   
       3 . A method of treating a neurological condition in an animal host in need there of comprising: administering to said animal host an effective amount of a compound as depicted in formula (II), wherein formula (II) is as follows: 
     
       
         
         
             
             
         
       
     
     wherein R 1 =Br, Cl, I or F. 
   
   
       4 . A method of treating a neurological condition in an animal host comprising: administering an effective amount of 5-6-bromo-N—N-dimethylryptamine, wherein said neurological condition is selected from the group consisting of depression and anxiety. 
   
   
       5 . A method to sedate of an animal host comprising: administering an effective amount of 5-dibromo-N,N-dimethyltryptamine to said animal host. 
   
   
       6 . A method of treating, a neurological condition in an animal host in need there of comprising:
 administering to said animal host an effective amount of a compound as depicted in formula (V), wherein formula (V) is as follows:   
     
       
         
         
             
             
         
       
     
   
   
       7 . A method of treating a neurological condition in an animal host comprising: administering an effective amount of 3-bromotyramine to said animal host. 
   
   
       8 . A method of treating a neurological condition in an animal host in need there of comprising: administering to said animal host an effective amount of a compound as depicted in formula (III), wherein formula (III) is as follows: 
     
       
         
         
             
             
         
       
     
   
   
       9 . A composition as depicted in formula (IV), wherein said formula (IV) is as follows: 
     
       
         
         
             
             
         
       
     
   
   
       10 . A pharmaceutical formulation comprising the compound of  claim 9  and a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient. 
   
   
       11 . A method of treating a neurological condition in an animal host in need thereof comprising: administering an effective amount of the composition of  claim 9  to an animal host. 
   
   
       12 . A method of treating a neurological condition in an animal host in need thereof comprising: administering an effective amount of the composition of  claim 10  to an animal host. 
   
   
       13 . A pharmaceutical formulation comprising a compound as depicted in formula (II), wherein formula (II) is as follows: 
     
       
         
         
             
             
         
       
     
     and a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient, wherein R 1 =Br, Cl, I or F. 
   
   
       14 . The pharmaceutical formulation of  claim 13  wherein said compound is selected from the group consisting of: 5-bromo-N,N-dimethyltryptamine and 5-6-dibromo-N—N-dimethyltryptamine. 
   
   
       15 . A pharmaceutical formulating comprising of a halodopamine derivative and a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient, wherein said halodopamine is 3-bromotyramine.